<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174693</url>
  </required_header>
  <id_info>
    <org_study_id>MAESTRO-001</org_study_id>
    <nct_id>NCT01174693</nct_id>
  </id_info>
  <brief_title>Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myung In Pharmaceutical Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the preventive effect of stroke between triflusal and
      clopidogrel in ischemic stroke patient based on the cytochrome P450 2C19 (CYP2C19)
      polymorphism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel has anti-platelet activity by irreversible inhibition of the P2Y12 platelet
      receptor. Clopidogrel must be converted into an active metabolite in order to show
      anti-platelet activity. Hepatic CYP2C19 enzyme is one of the key hepatic enzymes which
      convert clopidogrel into active metabolite and its genetic polymorphism is related to
      clopidogrel resistance. CYP2C19 poor or intermediate metabolizer groups show reduced
      anti-platelet activity of clopidogrel compared to extensive metabolizer group.

      This study is designed to prove the superiority of the triflusal in preventing recurrent
      stroke over the clopidogrel in ischemic stroke patient with poor or intermediate metabolizer
      of CYP2C19 polymorphism. Also we plan to prove that clopidogrel resistance is related to
      CYP2C19 polymorphism by comparing the ischemic preventive effect of clopidogrel between
      groups of different CYP2C19 polymorphism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first recurrent stroke</measure>
    <time_frame>2.8 to 4 years</time_frame>
    <description>The study will finish at least 2 years after the recruit of 1080th patients. Until the finish, patients will continuously take study medications and visit every 3months at the study site.
We will measure primary outcome during the follow-up period (minimum 2.8 years to maximum 4 years - maximum time is determined by estimated enrollment time period of 2.8 years).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first of composite cardiovascular events, MI or coronary artery revascularization and ischemic stroke</measure>
    <time_frame>2.8 to 4 years</time_frame>
    <description>The study will finish at least 2 years after the recruit of 1080th patients. Until the finish, patients will continuously take study medications and visit every 3months at the study site.
We will measure secondary outcomes during the follow-up period (minimum 2.8 years to maximum 4 years - maximum time is determined by estimated enrollment time period of 2.8 years).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">795</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plavix® 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triflusal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disgre® 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triflusal</intervention_name>
    <description>Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014</description>
    <arm_group_label>Triflusal</arm_group_label>
    <other_name>Disgren®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who have non-cardiogenic ischemic stroke of TOAST classification within 30
             days prior to screening

          2. ≥ 20 years of age; adult, at the date of signing the informed consent

          3. Written informed consent

        Exclusion Criteria:

          1. History for bleeding tendency or recent major bleeding within 2 weeks

          2. Chronic liver disease (ALT &gt; 100 IU/L or AST &gt; 100 IU/L) or renal dysfunction
             (creatinine &gt; 4.0 mg/dl)

          3. Thrombocytopenia (platelet &lt; 100,000mm3)

          4. Any contraindication of antiplatelet agent

          5. Severe congestive heart failure

          6. Patients who need to take anticoagulants or two or more antiplatelet agents

          7. Severe concomitant disease with the expected survival less than 2 years

          8. Pregnant or nursing

          9. Any drug clinical trials within 30 days of signing the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KyungYul Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Wonju Christian Hospital, Yonei University Wonju College of Medicine</name>
      <address>
        <city>Wonju-si</city>
        <state>Gangwon-do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, CHA Bundang Medical Center, CHA University School of Medicine</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changwon Fatima Hospital</name>
      <address>
        <city>Changwon</city>
        <state>Gyeongsangnam-do</state>
        <zip>641-560</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, National Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>100-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Gangnam Severance Hospital, Yonsei Univ. College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>139-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>KyungYul Lee</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>prospective</keyword>
  <keyword>randomized</keyword>
  <keyword>open label</keyword>
  <keyword>multi-center</keyword>
  <keyword>double-blind for CYP2C19 genotypes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Triflusal</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Salicylates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

